IDC News
Immune Design Corp. Announces Appointment of Dr. Bruce L.A. Carter as Executive Chairman and Director
PRNewswire - November 23, 2009
Immune Design Corp. (IDC) announced
today that Dr. Bruce L.A. Carter has joined IDC as Executive Chairman.
Dr. Carter has a successful track record in biotechnology executive
management. He was the former Chief Executive Officer at ZymoGenetics,
in Seattle, WA and Chief Scientific Officer at Novo Nordisk, Copenhagen,
Denmark.
more...
IDRI and Immune Design Corp. Enter License Agreement on GLA Vaccine Adjuvant
Seattle - November 20, 2008
IDRI (Infectious Disease Research Institute) and Immune Design Corp. announced today that they have entered into an agreement pursuant to which Immune Design Corp. is granted a worldwide exclusive license for the research, development, and commercialization of IDRI's Glycopyranosyl Lipid Adjuvant (GLA) technology for products targeting a number of indications. Focusing on its mission to fight infectious diseases of the developing world, IDRI retains worldwide exclusive rights to GLA for selected diseases affecting predominately the developing world. Under the agreement, IDRI will receive an upfront payment, milestones, and royalty payments as well as shares in Immune Design Corp. Further details on the financial terms were not disclosed. IDRI and Immune Design Corp. Enter License Agreement.
more...
Immune Design, Led By Star Scientists, Raises $18 Million To Build Vaccine Company
Luke Timmerman (Xconomy) - June 23, 2008
Vaccines are coming back in a big way. Immune Design, a Seattle-based startup vaccine company, made that clear today when it said it raised $18 million in an initial round of venture capital.
more...
If you are a member of the media, please contact us regarding any potential news interest.